We are submitting herewith the annual report for the FY 2025-26

1st August, 2026 To, To, The Manager - Corporate Relationship The Manager - Corporate Compliance Dept. National Stock Exchange of India Ltd BSE Limited Exchange Plaza, Plot No.C-1, P. J. Towers, Dalal Street G Block, BKC, Bandra (E), Fort, Mumbai - 400 001 Mumbai 400 051 Scrip Code: BSE - 524500 Scrip Code: NSE - KILITCH Sub: Annual Report for the financial year 2025-26 and Notice of 34th Annual General Meeting Pursuant to Regulations 30 and 34 of Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations 2015 (“Listing Regulations”), we are submitting herewith the Annual Report for the financial year 2025-26 along with notice of 34th Annual General Meeting of the Company which is being sent today through electronic mode to those members whose e-mail addresses are registered with the Company/ Registrar & Share Transfer Agent / Depository Participant(s), in accordance with the MCA Circulars and SEBI Circulars. The 34th Annual General Meeting of the Company (AGM) is scheduled to be held on Thursday, 27th August, 2026 at 9:00 am (IST) through Video Conferencing or Other Audio Visual Means. The Notice of 34th Annual General Meeting and Annual Report is available on the website of the Company at www.kilitch.com We request you to kindly take the same on record and acknowledge the receipt. Thanking you, For Kilitch Drugs (India) Limited Mukund Mehta Managing Director ASIA MIDDLE EAST AFRICA LATIN AMERICA K PI EL NIT C GH D ER EU NG FS ( EIN LD DI A F) A L CIM ILIT ITED Y Building the Future of GLOBAL HEALTHCARE Engineering Global Healthcare INNOVATION QUALITY COMPLIANCE GLOBAL REACH Kilitch Group - At a Glance 01 Financial Statements: Mr. Dipen J. Jain C Sharat & Associates 226, 2nd Floor, Champaklal, Udyog Bhavan, Next to MTNL, Sion East, Mumbai - 400022 MUFG Intime India Private Limited E-mail : rnt.helpdesk@in.mpms.mufg.com Mr. Sunil Jain (Chartered Accountant) Corporate Information Statutory Reports Financial KILITCH DRUGS (INDIA) LIMITED 3 50+ KILITCH GROUP Manufacturing Countries AT A GLANCE Facilities Presence India (2) | Ethiopia (1) Across Continents Kilitch Drugs (India) Limited is a globally 230+ 200+ compliant pharmaceutical company Dedicated Products committed to improving global Professionals Portfolio healthcare through innovation, quality and sustainable growth. Passionate Qualified Committed Across Multiple Therapeutic Areas GLOBAL PRESENCE Growing with trusted partnerships Strengthening our presence Delivering value with care Building healthier Expanding access tomorrows to quality medicines OUR STRENGTHS Designed and Strong Advanced Robust Quality Global Sustainability Built to Meet R&D and Technology & Systems & Reach with at the Core of EU GMP & USFDA Innovation Smart Regulatory Diverse Everything Standards Pipeline Manufacturing Excellence Portfolio We Do OUR CERTIFICATIONS FDA Philippines MOH Cambodia AF uo A to hdd om M rii tne yid s oi tc fr i a En te tio h a n ion a pd n i aH d (e C Fa Molt nh Ht ArC o Ca lr Ae ) MINIS LT 'HE YR GE I ED NE E L A PU S BA LN IQTE U EET DE NAFDAC Nigeria DIRECTION GENERALE DE LA SANTE AQC GLOBAL LLC AQC GLOBAL LLC FDA Ghana PPB Kenya NMPB Sudan MOH Zambia Rwanda FDA SBDMA YEMEN ISO 13485:2016 ISO 9001:2015 Annual Report 2025-26 01 Corporate Information Statutory Reports Financial KILITCH DRUGS (INDIA) LIMITED MANUFACTURING EXCELLENCE PEN GREENFIELD FACILITY BUILT FOR THE FUTURE. READY FOR THE WORLD. PEN, MAHARASHTRA, INDIA State-of-the-art greenfield pharmaceutical manufacturing facility designed to global standards. 14+ 18,000+ State-of-the-art Designed for Designed and Built Technology Scalability & to Meet EU GMP & Acres Sq. Mtr. & Automation Sustainability USFDA Standards Campus Built-up Area FACILITY HIGHLIGHTS KEY CAPABILITIES Advanced sterile injectable manufacturing High capacity & flexible (Vials, Ampoules, Lyophilized) manufacturing lines Nutraceuticals & Effervescent Automation & AI enabled (Tablets, Powder) systems Ophthalmic preparations Digital Manufacturing Integrated QC & Microbiology Execution System (MES) laboratories Warehouse with automated Real time monitoring material handling systems & data integrity Sustainable design with green End to end quality initiatives and energy-efficient assurance systems DESIGNED TO DELIVER Our Pen facility enables us to meet the growing global demand for high quality pharmaceuticals while ensuring operational excellence, regulartory compliance, and QUALITY INNOVATION PEOPLE PATIENTS PLANET environmental responsibility. Built-in Driven Focused Committed Protected Corporate Information Statutory Reports Financial KILITCH DRUGS (INDIA) LIMITED Year of Purpose and Performance FINANCIAL OPERATIONAL & GOVERNANCE ₹ 23,547.49 35 Years of Experience Lakh Consolidated Total Income Set up of New Manufacturing Facility at ₹ 4,628.47 Pen-Maharashtra Lakh EBITDA 70% Revenue from Export ₹ 4,155.37 Lakh 50% Independent Directors on board Profit before Tax ₹ 3,239.96 Lakh 100% Shareholders inquery Resolved Profit after Tax 45% Female Employees ₹ 9.57 Earning Per Share 55.95 Lakh CSR Spent Our People Together Towards Excellence The Company believes that empowered employees and strong teamwork are key drivers of organisational success. We continue to cultivate a workplace that values collaboration, inclusivity, and collective achievement. During the year, the Company further strengthened its talent management framework by enhancing its capabilities across talent acquisition, leadership development, employee engagement, employer branding, diversity and retention. During FY 2025-26 we have excellent work team having approx. 45% strength of women employees in each department while creating & fostering inclusive and collaborative work environment. The Company reinforced its commitment to employee well-being through structured learning and development programmes and workplace wellness practices, thereby promoting sustainable employee growth and organizational excellence. Annual Report 2025-26 03 Corporate Information Statutory Reports Financial KILITCH DRUGS (INDIA) LIMITED Managing Directors’ Perspective We remained focused on what has always defined us-integrity, quality, innovation and disciplined execution. Dear Shareholders, Investing Today for Tomorrow's Growth continues to develop differentiated formulations, improve existing products It gives me great pleasure to present the The successful completion of our new and optimise manufacturing processes, Annual Report of your Company for the greenfield manufacturing facility at Pen, helping us remain competitive in evolving Financial Year 2025–26. Maharashtra marks a defining milestone. markets. Designed with advanced manufacturing The past year tested businesses across the technologies, AI-enabled quality systems Creating Value Responsibly globe. Geopolitical conflicts, inflationary and digitally integrated production pressures, supply chain disruptions and processes, the facility has been developed We remain committed to Environmental, volatile commodity prices continued to to meet WHO, EU-GMP and USFDA Social and Governance (ESG) principles create uncertainty in the global economy. standards. As operations commence in through ethical governance, environmental Despite these headwinds, the phases, it will strengthen manufacturing stewardship, employee development and pharmaceutical industry once again capabilities, improve supply chain community engagement. demonstrated its resilience, driven by resilience and support long-term growth. growing healthcare awareness, an ageing Looking Ahead population, the rising burden of chronic Strengthening Our Manufacturing diseases, and the continued need for Foundation As we enter FY 2026–27, we remain affordable, high-quality medicines. optimistic. The commissioning of our Pen Our Mumbai facility continues to be the facility, investments in technology and Against this challenging backdrop, your backbone of our manufacturing network, e [Showing first 8,000 characters — download PDF for full document]